Deruxtecan pharma grade API is the unconjugated free base of the topoisomerase I inhibitor designated DXd, identified by CAS 1599440-33-1, molecular formula C₂₆H₂₄FN₃O₆, and molar mass 493.49 g·mol⁻¹. The material is supplied as a white to off-white powder for further pharmaceutical processing into oral solid, granulated, and injectable finished dosage forms. Although the drug substance is manufactured to pharmaceutical monograph alignment, the predominant industrial use of deruxtecan is as a conjugation-ready cytotoxic payload in antibody–drug conjugates for intravenous infusion; published clinical data for oral administration of unconjugated deruxtecan is limited. The product may be specified as the free base anhydrous polymorph with controlled residual solvents, elemental impurities, and particle size distribution, subject to the manufacturer’s certificate of analysis.

Physicochemical Identity and Method Alignment

Because no compendial monograph for deruxtecan is published in USP or Ph. Eur., the product is controlled against an internal specification. The release profile includes assay and related substances by HPLC under USP 621, residual solvents under USP 467 aligned with ICH Q3C, water content by Karl Fischer titration under USP 921, residue on ignition, elemental impurities under USP 232/233 aligned with ICH Q3D, polymorphic form by X-ray powder diffraction under USP 941, and particle size distribution by laser diffraction under USP 429. For injectable processing, bacterial endotoxin and, where the API is sterilized before final compounding, sterility are also controlled.

Model designations are manufacturer-specific. Injectable-grade material is typically differentiated from oral-grade material by lower bioburden, lower endotoxin, and smaller particle size to meet parenteral requirements; oral-grade material may allow a broader particle size distribution but still requires containment and blend uniformity. The product described here is the free base; salt, solvate, or co-crystal forms are separate items and should not be interchanged without comparative dissolution and stability studies under ICH Q1A(R2).

The solid-state form is controlled because amorphous content can accelerate degradation and alter dissolution. The API is packaged in sealed, light-resistant containers under inert gas. Water vapor transmission rate of the primary container is controlled to support the retest period; long-term stability is evaluated under ICH Q1A(R2) at 25 °C/60 % RH and accelerated storage at 40 °C/75 % RH. Hydrolytic degradation of the lactone ring and oxidative degradation of the indolizinone core are monitored by forced degradation under ICH Q1A(R2) and ICH Q1B. The acceptance criterion for total related substances is established from stability data; no public compendial specification exists.

For oral solid dosage development, containment is the controlling parameter because deruxtecan is handled as a potent cytotoxic payload. Direct compression, roll compaction, and low-shear wet granulation are evaluated under barrier-isolator or split-valve transfer systems with airborne monitoring validated to ISO 14644-1 and surface wipe limits defined by site industrial hygiene policy. The free base has limited aqueous solubility; dissolution-rate-limited absorption is managed through particle size reduction. Micronization below 10 µm may be required for dissolution enhancement, but the resulting cohesive powder can create flow inconsistency on rotary tablet presses. Process development therefore evaluates dry granulation to densify the milled drug without introducing liquid binders that could alter the solid-state form or increase amorphous content.

Granule-based processing is commonly used when the unit dose is low, at 1 mg or less per unit, because direct compression of a sub-1 % drug-load blend requires geometric dilution or trituration to meet content uniformity under USP 905. The drug substance is dispersed in a pre-blend with lactose monohydrate or microcrystalline cellulose, then granulated in a high-shear mixer; the wet mass is passed through a 1.0–1.5 mm screen and dried in a fluid-bed dryer with inlet air dew point controlled below 5 °C to limit moisture uptake. High-shear granulation endpoint is monitored by impeller power draw; typical tip speed of 3–6 m/s is used in early development, but the optimal range is formulation-dependent. These numerical ranges are typical process set points from solid dosage manufacturing, not deruxtecan-specific public data; site qualification must confirm them.

Capsule filling of deruxtecan-containing blends is performed on tamping-pin or dosator equipment under containment. The choice between tablet and capsule is driven by the need to avoid compression-induced polymorphic transformation or to accommodate micronized drug with poor flow. For capsule formulations, the powder bed may be pre-granulated or blended with a glidant such as colloidal silicon dioxide at up to 1.0 wt%; magnesium stearate is kept at the lower end of the typical 0.5–1.5 wt% range because hydrophobic lubricant excess can retard dissolution of a poorly soluble compound.

What Limits Sterile Filtration and Solubilization of the Injectable Grade?

Injectable processing of unconjugated deruxtecan is constrained by limited aqueous solubility of the free base at physiological pH. The drug substance is usually dissolved in a water-miscible organic solvent such as dimethyl sulfoxide or N,N-dimethylacetamide before compounding, then diluted into a buffered vehicle containing a solubilizer or pH modifier. Published solubility data for deruxtecan in specific parenteral vehicles is limited. Aseptic filtration through a 0.22 µm membrane rated per ASTM F838-20 is the preferred sterilizing-grade step for formulations that cannot withstand terminal sterilization; filter adsorption and extractables are assessed because the free base can bind to membrane materials.

Injectable-grade quality requires bacterial endotoxin below the finished-product limit calculated from the maximum dose per USP 85; a common calculation is 5.0 EU/kg body weight per hour for intravenous routes, but product-specific limits are derived from clinical dose. Subvisible particulate matter is measured by light obscuration per USP 787, and visible particles per USP 790. Sterility of the finished product is demonstrated by membrane filtration or direct inoculation under USP 71.

Oral and injectable specification divergence is route-specific. Injectable-grade material requires bacterial endotoxin control under USP 85 and particulate control under USP 787/790 that are not applicable to nonsterile oral solid forms. Conversely, oral solid forms require particle-size and flowability control under USP 429 and content uniformity under USP 905. Both grades require elemental impurity control under ICH Q3D, but the permitted daily exposure is route-specific and should be calculated from the daily dose of the finished product.

When the Hydroxyacetyl Side Chain Determines ADC Linker Selection

The structural distinction of deruxtecan relative to exatecan is the hydroxyacetyl substituent that provides a conjugation handle for cleavable linker attachment. In commercial ADC processes, the free drug is not tableted or encapsulated as a final dosage form; it is conjugated to a peptide-based cleavable linker and then to a monoclonal antibody. The resulting antibody–drug conjugate is formulated as an intravenous infusion, and the free drug is released after internalization and lysosomal cleavage. This route of administration is the primary clinical use of deruxtecan; oral and injectable formulations of unconjugated drug are development-stage concepts rather than marketed products.

In commercial trastuzumab deruxtecan, the target drug-to-antibody ratio is approximately 8; drug-to-antibody ratio and drug distribution are measured by hydrophobic interaction chromatography and reversed-phase HPLC under ICH Q2(R1) method validation. Conjugation process variability is controlled by reaction pH, temperature, and quenching time; these parameters are confidential to the ADC dossier. The free drug is released after internalization and lysosomal cleavage, and published ADC studies report bystander killing in heterogeneous tumor models because the unconjugated payload is membrane-permeable.

Differences from topotecan, irinotecan, SN-38, and exatecan are defined by both molecular design and manufacturing risk. Irinotecan is a prodrug requiring carboxylesterase-mediated conversion to SN-38; deruxtecan is an already-active topoisomerase I inhibitor after linker release, although the free base is not used directly as an oral or injectable drug in an approved product. Topotecan contains a basic tertiary amine side chain that improves water solubility and permits oral capsule and injectable formulations; deruxtecan lacks this basic side chain and therefore exhibits different solubility and formulation behavior. Exatecan shares the fluorinated tetracyclic core but lacks the hydroxyacetyl linker handle, limiting its use in current linker-payload platforms. SN-38 is a naturally derived active metabolite with a phenolic hydroxyl; deruxtecan is a synthetic derivative with a fluorinated core and a hydroxyacetyl side chain.

These structural differences alter lactone stability, membrane permeability, and potency in tumor cell lines. Published studies comparing deruxtecan and SN-38 report cell-line-dependent potency differences; no single universal ratio should be applied. The choice of deruxtecan over topotecan or irinotecan in ADC development is driven by its compatibility with peptide-cleavable linker chemistry and its reported bystander killing properties, not by a directly superior oral bioavailability profile.

Comparative Camptothecin Payload Profiles

The free base camptothecin lactone ring is pH-sensitive; the closed lactone form predominates below approximately pH 5.0, while the ring-opened carboxylate form increases at pH 7.4. For deruxtecan, published pH-rate data is limited, but the structural class imposes similar formulation constraints. Batch-to-batch variance in particle size and residual solvent content can shift dissolution and compressibility behavior; therefore, release testing must be matched to the intended finished dosage form rather than relying on a single generic API specification.